HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.4%

Neg 0% Neu 91.4% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.